Last reviewed · How we verify

Midodrine Oral Tablet — Competitive Intelligence Brief

Midodrine Oral Tablet (Midodrine Oral Tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1 adrenergic agonist. Area: Cardiovascular.

marketed Alpha-1 adrenergic agonist Alpha-1 adrenergic receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Midodrine Oral Tablet (Midodrine Oral Tablet) — Institute of Liver and Biliary Sciences, India. Midodrine is an alpha-1 adrenergic agonist that increases blood pressure by constricting blood vessels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Midodrine Oral Tablet TARGET Midodrine Oral Tablet Institute of Liver and Biliary Sciences, India marketed Alpha-1 adrenergic agonist Alpha-1 adrenergic receptor
Phenylephrine 1.0%/ Ketorolac 0.3% Phenylephrine 1.0%/ Ketorolac 0.3% University of Florida marketed Combination ophthalmic decongestant and NSAID Alpha-1 adrenergic receptor (phenylephrine); COX-1 and COX-2 (ketorolac)
amlodipine, hydralazine, terazosin or hydrochlorothiazide amlodipine, hydralazine, terazosin or hydrochlorothiazide Tulane University School of Medicine marketed Antihypertensive combination (calcium channel blocker, direct vasodilator, alpha-1 antagonist, thiazide diuretic) L-type calcium channel (amlodipine); vascular smooth muscle (hydralazine); alpha-1 adrenergic receptor (terazosin); sodium-chloride cotransporter (hydrochlorothiazide)
Topical cyclopentolate and phenylephrine Topical cyclopentolate and phenylephrine Dar El Oyoun Hospital marketed Anticholinergic agent + alpha-1 adrenergic agonist Muscarinic acetylcholine receptor (cyclopentolate); alpha-1 adrenergic receptor (phenylephrine)
Fexofenadine HCl + Pseudoephedrine HCl Fexofenadine HCl + Pseudoephedrine HCl Dr. Reddy's Laboratories Limited marketed Antihistamine + decongestant combination H1 receptor (fexofenadine); alpha-1 adrenergic receptor (pseudoephedrine)
Oxymetazoline 0.05% w/v Oxymetazoline 0.05% w/v Brian J Lipworth marketed Alpha-1 adrenergic agonist (nasal decongestant) Alpha-1 adrenergic receptor
Bupivacaine/epinephrine/dexamethasone Bupivacaine/epinephrine/dexamethasone Cedars-Sinai Medical Center marketed Local anesthetic combination Voltage-gated sodium channels (bupivacaine); alpha-1 adrenergic receptors (epinephrine); glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-1 adrenergic agonist class)

  1. Allergan · 2 drugs in this class
  2. EMS · 1 drug in this class
  3. Institute of Liver and Biliary Sciences, India · 1 drug in this class
  4. Medical University of Graz · 1 drug in this class
  5. Rawalpindi Medical College · 1 drug in this class
  6. Tehran Heart Center · 1 drug in this class
  7. Actavis Inc. · 1 drug in this class
  8. University Tunis El Manar · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Midodrine Oral Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/midodrine-oral-tablet. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: